NuvOx Pharma’s NanO2 Shows Positive Results in Phase Ib/II Stroke Trial

Positive results of NuvOx Pharma’s NanO2 (DDFPe) in the treatment of stroke have been published at the International Stroke Conference. A randomized Phase Ib/II trial tested acute ischemic stroke patients given placebo or low, medium, or high doses of NanO2. The primary endpoint was safety, which was demonstrated at all three dose levels. A secondary endpoint was the modified Rankin Scale (mRS), a measure of how independently patients can live in the weeks and months after the stroke. The high dose group suggested improvement in the mRS at 30 days and 90 days.


See full results

Recent Posts

See All

Tucson, AZ, May 16th, 2022 - https://www.pr.com/press-release/861616 NuvOx Pharma has been issued US Patent No. 11,304,899, entitled “Compositions of fluorocarbon nanoemulsion, and methods of prepara

Tucson, AZ, May 9th, 2022 – https://www.pr.com/press-release/861001 NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases whe